Unilumin, Megapixel VR and Userful Certify Advanced AV and LED Solutions for the Enterprise
2.2.2023 09:00:00 EET | Business Wire | Press release
Userful Corporation, the leading Platform-as-a-Service (PaaS) provider in the Enterprise AV-over-IP market, and Unilumin a world-class LED solution provider of high-quality LED display and lighting products alongside Megapixel VR have certified the integration of their advanced AV technologies.
This validation enables enterprise customers to modernize AV and LED deployments for control rooms, digital signage, meeting spaces and artistic video walls.
Unilumin’s award-winning, market-proven LED display technology and manufacturing expertise along with its successful deployment history pair strongly with Userful’s software-defined AV-over-IP platform to deliver an unsurpassed, centrally managed, secure, and scalable solution for a multitude of AV business applications.
“We are pleased to certify this solution with Userful to further enhance our DV-LED + Megapixel platforms and to provide customers an integrated choice for the broad range of enterprise applications that employ DV-LED,” said Unilumin President, Chris Danley.
“Through the testing and certification of our technologies, Unilumin, Megapixel, and Userful are advancing enterprise applications and providing assurances to AV and IT departments that our solution will meet and exceed expectations,” said Megapixel CEO Jeremy Hochman.
“As we continue to advance our next-generation AV platform, we are excited to collaborate with technology leaders to create best-in-class solutions. Integrating Unilumin and Megapixel’s state-of-the-art displays and controllers with Userful’s platform will provide a superior and unsurpassed solution for the digitally transformed enterprise,” said John Marshall, CEO, Userful.
A certified solution brief that provides an overview and specifications for this multiproduct solution can be found at userful.com/unilumin. The solution will be presented publicly in Unilumin’s booth at InfoComm 2023 in Orlando, Florida.
About Userful
Userful is the world’s leading platform-as-a-service provider in the Enterprise AV-over-IP market—the fastest-growing segment of the IT industry, forecasted to grow from today’s $3B to $51B by 2027, a 60 percent 5-year CAGR. Userful’s software-defined solution is disrupting the market with a Platform-as-a-Service (PaaS) model that allows customers to choose from a suite of highly-integrated AV applications (SaaS offerings, secure, SSO, integrated UI) to support modern service needs across the enterprise. From corporate signage to control room solutions to streaming platforms and data metrics, Userful's solutions enable modernized business operations for IT leaders and the functional departments they support. Userful helps organizations advance the way they work, learn and govern with secure, scalable, and centrally managed solutions for employee and customer engagement worldwide.
About Unilumin
Unilumin is a leading manufacturer of LED display products. In the field of Virtual Production, Unilumin has provided products and services for various industries such as film, XR, broadcast, and commercial. With an office and showroom in NYC and a 36,000+ sq. ft. Orlando Florida facility featuring a service repair center and "Experience Center" showroom, Unilumin is adhering to the corporate mission of "Together, for a Brighter Future", by providing cutting-edge LED products with an advanced sense of designs and one-stop solutions.
About Megapixel VR
Megapixel VR is an innovative technology partner dedicated to delivering fast-tracked, customized, state-of-the-art LED processing and monitoring to the world’s leading entertainment, film & TV, and architectural applications. Superior product design development, manufacturing expertise, and successful deployment, Megapixel delivers unsurpassed visual performance for any project and looks forward to making the world’s next iconic projects a reality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201006123/en/
Contact information
Danielle Alfaro
communications@userful.com
403-923-6723
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom